Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Analyst Sees Deteriorated Treatment Effect Of Blueprint’s Much Awaited Mastocytosis Data

By Vandana Singh
August 17, 2:56 PM
Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM).  The topline data indicates that…

BPMC

Read More
2 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories
  • Trading Ideas

Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022

By Vandana Singh
August 17, 2:52 PM
As the U.S. plans to get out of the crisis phase, the Biden administration said it would stop buying…

BNTX

Read More
1 minute read
  • Contracts
  • General
  • News

ADM Partners With New Culture For Animal-Free Dairy Products

By Shivani Kumaresan
August 17, 2:51 PM
Archer-Daniels-Midland Co (NYSE:ADM) has signed a strategic partnership with New Culture, an animal-free dairy company, to develop and commercialize alternative…

ADM

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Reiteration
  • Trading Ideas

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial

By Vandana Singh
August 17, 2:28 PM
Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…

PFE

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Downgrades
  • General
  • Health Care
  • Price Target
  • Short Ideas
  • Small Cap
  • Trading Ideas

What’s Going On With Teladoc Health Shares Today?

By Dylan Wechsler
August 17, 2:21 PM
Shares of Teladoc Health Inc. (NYSE: TDOC) are trading lower today following an analyst downgrade. Why Is It Moving?

TDOC

Read More
2 minute read
  • Entertainment
  • General
  • News
  • Tech
  • Topics
  • Trading Ideas

Take That, Elon Musk! Ford F-150 Lightning Gives Tesla Model 3 A Boost

By AJ Fabino
August 17, 2:09 PM
There are presently more than 46,000 public EV charging stations in the United States, with a total of more than 115,000 individual (EVSE) charging ports, according to the Alternative Fuels Data Center of the Department of Energy.

F

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

Bluebird Bio PR Announces FDA Approval Of ZYNTEGLO

By Bill Haddad
August 17, 2:07 PM
ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels Management team to host conference

BLUE

Read More
1 minute read
  • Biotech
  • General
  • News

bluebird bio Says List Price Of Newly-Approved Gene Therapy Is At $2.8M

By Michael Horton
August 17, 1:48 PM
-Reuters

BLUE

Read More
1 minute read
  • Biotech
  • General
  • News

‘Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder’ -STAT

By Michael Horton
August 17, 1:39 PM
https://www.statnews.com/2022/08/17/bluebird-wins-fda-approval-for-gene-therapy-for-beta-thalassemia/?utm_content=bufferba14a&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic

BLUE

Read More
1 minute read
  • General
  • Media
  • Small Cap
  • Trading Ideas

Apple, IBM Get CNBC ‘Fast Money’ Mentions, While This Stock Popped Nearly 1% In Seconds

By AJ Fabino
August 17, 1:37 PM
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.

AAPL

Posts pagination

Previous 1 … 2,222 2,223 2,224 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service